Sai Life Sciences IPO: Overwhelming Response with 10.26 Times Subscription, Allotment Status and Key Details
The Sai Life Sciences IPO, open for subscription from December 11 to 13, received an overwhelming response, being subscribed 10.26 times overall. The price band for the issue was set between ₹522 and ₹549 per share.
Qualified Institutional Buyers (QIBs) were the biggest contributors, with their portion oversubscribed by a massive 30.93 times. The non-institutional investor segment was subscribed 4.92 times, while the retail investor portion saw a 1.37 times subscription.
How to Check Sai Life Sciences IPO Allotment Status
Investors who applied for the Sai Life Sciences IPO can check their allotment status via the BSE, NSE, or IPO registrar KFin Technologies websites. Here’s how:
On the BSE Website:
- Visit the BSE IPO allotment page.
- Select ‘Equity’ as the issue type.
- Choose ‘Sai Life Sciences’ from the dropdown menu.
- Enter your application number or PAN.
- Click ‘Search’ to view your allotment status.
On KFin Technologies Website:
- Go to the KFin Technologies IPO page.
- Select ‘Sai Life Sciences’ from the dropdown menu.
- Enter your PAN, application number, or DP/Client ID.
- Click ‘Submit’ to check your status.
Successful applicants will have the shares credited to their demat accounts, while refunds will be processed for unsuccessful bids on December 17.
Sai Life Sciences IPO Details
The Sai Life Sciences IPO raised ₹913 crore from anchor investors before it opened for subscription. The ₹3,043 crore issue includes a fresh equity issue of ₹950 crore and an Offer for Sale (OFS) of 3.81 crore shares worth ₹2,092 crore, offered by promoters and other stakeholders.
Out of the funds raised, ₹600 crore will be used for debt repayment, with the remaining funds allocated for general corporate purposes.
About Sai Life Sciences
Headquartered in Hyderabad, Sai Life Sciences provides a wide range of services across the drug discovery, development, and manufacturing value chain. The company specializes in small molecule new chemical entities (NCEs), serving global pharmaceutical and biotechnology innovators.
